Loading Fredun Pharmaceuticals…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 228 | 210 | 160 | 144 | 119 |
| Operating profit | 29 | 26 | 25 | 20 | 16 |
| Operating margin | 12.8% | 12.2% | 15.4% | 14.2% | 13.0% |
| Net profit | 13 | 11 | 10 | 9 | 7 |
| Net margin | 5.8% | 5.1% | 6.6% | 6.6% | 5.7% |
| EPS (₹) | 7.40 | 6.07 | 7.40 | 6.66 | 0.00 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 633 | 452 | 347 | 274 |
| Operating profit | 94 | 57 | 34 | 25 |
| Operating margin | 14.9% | 12.5% | 9.9% | 9.1% |
| Net profit | 33 | 20 | 16 | 11 |
| Net margin | 5.2% | 4.4% | 4.5% | 3.9% |
| EPS (₹) | 0.00 | 0.00 | 11.11 | 7.64 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 642 | 487 | 308 | 257 |
| Total liabilities | 360 | 346 | 186 | 161 |
| Shareholders’ equity | 282 | 141 | 121 | 96 |
| Total debt | 242 | 168 | 106 | 87 |
| Cash & equivalents | 65 | 1 | 1 | 3 |
| Debt / equity | 0.86 | 1.19 | 0.87 | 0.90 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 12 | -17 | -0 | -14 |
| Capital expenditure | -74 | -6 | -8 | -9 |
| Free cash flow | -62 | -23 | -8 | -24 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 11.6% | 14.0% | 12.9% | 11.2% |
| Return on assets | 5.1% | 4.0% | 5.1% | 4.2% |
| Net margin | 5.2% | 4.4% | 4.5% | 3.9% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for FREDUN. Finnhub coverage is limited for some India-listed stocks.